We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PharmaDiagnostics Launches the First SoPRano™ Assay Kit for In-House Assay Development
Product News

PharmaDiagnostics Launches the First SoPRano™ Assay Kit for In-House Assay Development

PharmaDiagnostics Launches the First SoPRano™ Assay Kit for In-House Assay Development
Product News

PharmaDiagnostics Launches the First SoPRano™ Assay Kit for In-House Assay Development


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PharmaDiagnostics Launches the First SoPRano™ Assay Kit for In-House Assay Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that does not require specialized equipment, announces the launch of its SoPRano™ assay kit, SoPRano CA1.

The kit allows users to couple their own proteins to SoPRano gold nanoparticles and build and run their own assays. This was previously available only as a service provided by PharmaDiagnostics, and the kit will now expand the accessibility and utility of the technology to customers.

SoPRano technology is based on a variant of the well-established surface plasmon resonance (SPR) phenomenon, and for the first time makes label-free screening available in high throughput on a standard plate-reader.

Label-free screening is an area of great interest and growth in pharmaceutical research. To date, the expanding SPR segment of this market has been dominated by providers of expensive specialist instrumentation that is unable, due to technical constraints, to provide the throughput required for routine screening.

With the launch of the SoPRano CA1, the first in a new family of kits, PharmaDiagnostics is now able to deliver on the promise of label-free SPR screening by enabling researchers to develop and run their own high-quality, cost-effective assays without the need for expensive capital equipment.

The kits enable users to develop assays for a range of applications, including fragment screening, focused high throughput screening (HTS), antibody discovery, and hit confirmation. The company also already offers SoPRano kits for a range of ADME and physicochemical properties, including plasma protein binding, pKa and redox potential.

PharmaDiagnostics' SoPRano label-free platform is the first SPR-based system to utilize standard plate-readers, and simple assay protocols. This increases for researchers, lowers barrier to adoption and also offers scalability, thus lowering costs, as it is not necessary to increase instrument expenditure to increase throughput.
Advertisement